Skip to navigation Skip to content

Clinical Trial: IMS001 in people with MS

Share

Details
Type of MS: PPMS|RRMS|SPMS
Treatment mode of action: To reduce disease activity
Number of Subjects: 30
Medication: human embryonic stem cell derived (hESC) mesenchymal stem cell (MSC) product to treat MS called IMS001
Location: Utah
Institutions: Rocky Mountain MS Research Group
370 E 9th Ave. Suite #106
Salt Lake City, Utah 84103 Contact Information
Please see below

Funding:

ImStem Biotechnology

Description

The purpose of this research is to determine the safety, tolerability, efficacy, and optimal dose regimen of an investigational human embryonic stem cell derived (hESC) mesenchymal stem cell (MSC) product to treat MS called IMS001.Taking part in this research will last for up to 5 years/61 months, consisting of a 1-month Screening Phase, a 12-month Treatment Phase, and a 48-month or more Long-term Follow-up Phase. The study will involve clinic visits that include clinical exams, electrocardiograms, MRI, blood draws, and on one or two visits, infusion treatment. This is an open-label study, which means you and the study doctor will know which group you are in and therefore which dose of study drug you are receiving.

Contact information:
Contact Name: Sue Griffiths/Tammy Hoyt
Phone:801-408-5700
Email:sgriffiths@rmmsc.com thoyt@rmmsc.com
 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.